Lymphoma Clinical Trials

Showing 781-800 of 2,926 trials

Whole Body MRI in Oncology

NCT06895291

Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.

LymphomaAdvanced Prostate CancerAdvanced Breast Cancer+3 more

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1,000 participantsStarted Oct 2023

Bologna, BO, Italy • Meldola, FC, Italy • Milan, MI, Italy

Not Yet RecruitingPhase 2

Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients

NCT06901999

This study is designed as an open-label, prospective, single-arm, single-center trial aimed at evaluating the efficacy and safety of MTX or Thiotepa combined with Orelabrutinib and standard chemotherapy regimens in the treatment of DLBCL patients with central nervous system involvement.

CNS Lymphoma

Ruijin Hospital23 participantsStarted Apr 2025

COMPLETEDPhase 3

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT03734016

This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

BeiGene652 participantsStarted Nov 2018

Little Rock, Arkansas, United States • Los Angeles, California, United States • Boulder, Colorado, United States +112 more locations

Whole Body MRI in Oncology

Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Related Searches

Gut Health in Children With Cancer

Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma